Dr. Hensing Discusses Studies in Stage III NSCLC

Thomas A. Hensing, MD
Published: Friday, Oct 06, 2017



Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non–small cell lung cancer (NSCLC).

Hensing says that the most exciting prospective study in stage III NSCLC is the PACIFIC trial, which evaluated durvalumab (Imfinzi) following concurrent chemoradiation.

The progression-free survival Kaplan-Meier curve in this trial was the first time an improvement in outcome was observed for patients with stage III disease.
 


Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non–small cell lung cancer (NSCLC).

Hensing says that the most exciting prospective study in stage III NSCLC is the PACIFIC trial, which evaluated durvalumab (Imfinzi) following concurrent chemoradiation.

The progression-free survival Kaplan-Meier curve in this trial was the first time an improvement in outcome was observed for patients with stage III disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x